| Title: |
HDL Composition, Heart Failure, and Its Comorbidities |
| Authors: |
Ahmed Diab; Carla Valenzuela Ripoll; Zhen Guo; Ali Javaheri |
| Source: |
Frontiers in Cardiovascular Medicine, Vol 9 (2022) |
| Publisher Information: |
Frontiers Media S.A., 2022. |
| Publication Year: |
2022 |
| Collection: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| Subject Terms: |
high-density lipoprotein (HDL); apolipoprotein A-I; apolipoprotein M; sphingosine-1-phosphate; heart failure; cardiomyopathy; Diseases of the circulatory (Cardiovascular) system; RC666-701 |
| Description: |
Although research on high-density lipoprotein (HDL) has historically focused on atherosclerotic coronary disease, there exists untapped potential of HDL biology for the treatment of heart failure. Anti-oxidant, anti-inflammatory, and endothelial protective properties of HDL could impact heart failure pathogenesis. HDL-associated proteins such as apolipoprotein A-I and M may have significant therapeutic effects on the myocardium, in part by modulating signal transduction pathways and sphingosine-1-phosphate biology. Furthermore, because heart failure is a complex syndrome characterized by multiple comorbidities, there are complex interactions between heart failure, its comorbidities, and lipoprotein homeostatic mechanisms. In this review, we will discuss the effects of heart failure and associated comorbidities on HDL, explore potential cardioprotective properties of HDL, and review novel HDL therapeutic targets in heart failure. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2297-055X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fcvm.2022.846990/full; https://doaj.org/toc/2297-055X |
| DOI: |
10.3389/fcvm.2022.846990 |
| Access URL: |
https://doaj.org/article/3638db6f2a8d4f0c8e6d8199ecb38ee2 |
| Accession Number: |
edsdoj.3638db6f2a8d4f0c8e6d8199ecb38ee2 |
| Database: |
Directory of Open Access Journals |